CDC20 and cancer: Preclinical exploration have shown that specific CDC20 inhibitors, including proTAME and Apcin, are effective against multiple types of malignant tumors, resulting in mitotic arrest and apoptosis and synergizing with clinically-relevant drugs [29–31].